Drug Firms Join In Stem Cell R&D Under EU Innovative Medicines Initiative
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest public-private partnerships to be announced under the EU’s Innovative Medicines Initiative includes the StemBANCC project involving 10 pharmaceutical companies and 23 academic institutions working together to develop patient-derived induced stem cell lines for drug development.